Literature DB >> 25438737

Negative regulation of RelA phosphorylation: emerging players and their roles in cancer.

Xinyuan Lu1, Wendell G Yarbrough2.   

Abstract

NF-κB signaling contributes to human disease processes, notably inflammatory diseases and cancer. Many advances have been made in understanding mechanisms responsible for abnormal NF-κB activation with RelA post-translational modification, particularly phosphorylation, proven to be critical for RelA function. While the majority of studies have focused on identifying kinases responsible for NF-κB phosphorylation and pathway activation, recently progress has also been made in understanding the negative regulators important for restraining RelA activity. Here we summarize negative regulators of RelA phosphorylation, their targeting sites in RelA and biological functions through negative regulation of RelA activation. Finally, we emphasize the tumor suppressor-like roles that these negative regulators can assume in human cancers.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  LZAP; NF-κB; PPM1A; Phosphatase; Tumor suppressor

Mesh:

Substances:

Year:  2014        PMID: 25438737     DOI: 10.1016/j.cytogfr.2014.09.003

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  22 in total

1.  LZAP is a novel Wip1 binding partner and positive regulator of its phosphatase activity in vitro.

Authors:  J Jacob Wamsley; Natalia Issaeva; Hanbing An; Xinyuan Lu; Lawrence A Donehower; Wendell G Yarbrough
Journal:  Cell Cycle       Date:  2016-12-27       Impact factor: 4.534

Review 2.  Gankyrin as a potential therapeutic target for cancer.

Authors:  Chongchong Wang; Li Cheng
Journal:  Invest New Drugs       Date:  2017-05-19       Impact factor: 3.850

Review 3.  A comprehensive overview of PPM1A: From structure to disease.

Authors:  Mao Li; Xingfeng Xu; Yan Su; Xiaoyun Shao; Yali Zhou; Jianguo Yan
Journal:  Exp Biol Med (Maywood)       Date:  2021-12-03

4.  A novel MYD88 mutation, L265RPP, in Waldenström macroglobulinemia activates the NF-κB pathway to upregulate Bcl-xL expression and enhances cell survival.

Authors:  T Nagao; G Oshikawa; S Ishida; H Akiyama; Y Umezawa; A Nogami; T Kurosu; O Miura
Journal:  Blood Cancer J       Date:  2015-05-15       Impact factor: 11.037

Review 5.  Post-Translational Modifications of RelB NF-κB Subunit and Associated Functions.

Authors:  Véronique Baud; Davi Collares
Journal:  Cells       Date:  2016-05-04       Impact factor: 6.600

6.  MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.

Authors:  Alf Spitschak; Claudia Meier; Bhavani Kowtharapu; David Engelmann; Brigitte M Pützer
Journal:  Mol Cancer       Date:  2017-01-26       Impact factor: 27.401

7.  Identification of immune-related biomarkers associated with tumorigenesis and prognosis in cutaneous melanoma patients.

Authors:  Biao Huang; Wei Han; Zu-Feng Sheng; Guo-Liang Shen
Journal:  Cancer Cell Int       Date:  2020-05-25       Impact factor: 5.722

8.  NF-κB-mediated lncRNA AC007271.3 promotes carcinogenesis of oral squamous cell carcinoma by regulating miR-125b-2-3p/Slug.

Authors:  Ze-Nan Zheng; Guang-Zhao Huang; Qing-Qing Wu; Heng-Yu Ye; Wei-Sen Zeng; Xiao-Zhi Lv
Journal:  Cell Death Dis       Date:  2020-12-12       Impact factor: 8.469

Review 9.  Role of the NFκB-signaling pathway in cancer.

Authors:  Longzheng Xia; Shiming Tan; Yujuan Zhou; Jingguan Lin; Heran Wang; Linda Oyang; Yutong Tian; Lu Liu; Min Su; Hui Wang; Deliang Cao; Qianjin Liao
Journal:  Onco Targets Ther       Date:  2018-04-11       Impact factor: 4.147

10.  Multiplexing information flow through dynamic signalling systems.

Authors:  Giorgos Minas; Dan J Woodcock; Louise Ashall; Claire V Harper; Michael R H White; David A Rand
Journal:  PLoS Comput Biol       Date:  2020-08-03       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.